Clinical Trials

Are you an adult who has asthma, or are you willing to be a healthy volunteer? This study aims to test a new and less invasive way to look at the levels of a protein called GSNOR in people who have asthma. High levels of this protein can lead to inflammation (swelling) in the airways. Normally, doctors measure GSNOR levels with bronchoscopy (a tube inserted through your mouth into your airways). But this often requires you to be sedated. In the new approach being studied here, you will breathe in a chemical that your body makes, called GSNO. Researchers will look at how much of the chemical is broken down in your breath. This will tell them what your GSNOR levels are. They will compare the levels between people who have asthma and people who do not to see whether the test works. To participate in this study, you should be between 18 and 80 years old and either have been diagnosed with asthma for at least a year or not have asthma and not smoke. This study is located in Cleveland, Ohio.

DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 24-27 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.

This is an observational - data and specimen collection study. There have been increasing reports of vaping-induced lung injury, including severe lung injury and rare cases of death. The mechanism by which vaping contributes to lung injury in susceptible persons is unknown, as is impact on chronic lung disease. The investigators aim to identify individuals with chronic electronic nicotine delivery device (ENDD) exposure and matched controls within our ongoing cohort of HIV+ and HIV-uninfected individuals, collect PFT data, bank respiratory and stool samples and collect clinical data for studies of clinical risk, inflammation, biomarkers, and the microbiome in the identification and modification of risk of progression to lung injury or chronic pulmonary disease.

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

Are you between 40 and 85 with worsening idiopathic pulmonary fibrosis? This study aims to test a new combination treatment for acute exacerbations, a life-threatening complication of idiopathic pulmonary fibrosis (IPF) that has no approved treatment. The treatment is meant to help stop part of the immune system from further injuring the lung tissue. To participate in this study, you must be between 40 and 85 years old and have worsening IPF. This study is located in Birmingham, Alabama; Boston, Massachusetts; Philadelphia, Pennsylvania; and Pittsburgh, Pennsylvania.

Are you a healthy adult between 40 and 90 years old and willing to help research? This study will test whether a new device called the OsciPulse system, which is designed to repeatedly compress a person’s legs, can improve blood flow through the legs to prevent or treat varicose veins. To participate in this study, you must be 40 to 90 years old and healthy. This study takes place in Philadelphia, Pennsylvania.